Histamine and Seizures: Implications for the Treatment of Epilepsy

CNS Drugs

Volumn 5, Issue 5, 1996, Pages 321-330

  Yokoyama, Hiroyuki ^a   Iinuma, Kazuie ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBINOXAMINE; CHLORPHENIRAMINE; CLEMASTINE; CLOBENPROPIT; CYPROHEPTADINE; DIPHENHYDRAMINE; HISTAMINE; HISTAMINE H3 RECEPTOR ANTAGONIST; HYDROXYZINE; KETOTIFEN; MEPYRAMINE; METHAPYRILENE; N (1 ADAMANTYL) N',N' [3 (1H IMIDAZOL 4(5) YL)PENTAMETHYLENE]FORMAMIDINE; PROMETHAZINE; THIOPERAMIDE; TRIPELENNAMINE; UNCLASSIFIED DRUG;

EPILEPSY; HUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE;

EID: 0029945360     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605050-00002     Document Type: Review

References (70)

1. Yamatodani A, Ainagaki N, Panula P, et al. Structure und functions of the histaminergic neuron system. In: Uvnäs E, editor. Handbook of experimental pharmacology. Vol. 97. Histamine and histamine antagonists. Berlin: Springer-Verlag, 1991: 231-83
2. Watanabe T, Yamatodani A, Maeyama E, et al. Pharmacology of α-fluoromethylhistidine, a specific inhibitor of histidine decarboxylase. Trends Pharmacol Sci 1990; 11: 363-6
3. Schwartz JC, Lampart C, Rose C. Histamine formation in rat brain in viro, effect of histidine loads. J Neurochem 1972; 19: 801-10
4. Hill SJ. Distribution, properties and functional characteristics of three classes of histamine receptor. Pharmacol Rev 1990; 42: 45-83
5. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832-7
6. Arrang JM, Garbarg M, Lancelot JC. Highly potent and selective ligands for histamine H3 receptors. Nature 1987; 307: 117-23
7. Green JP. Histamine. In: Lajtha A, editor. Handbook of neurochemistry. London: Plenum Press, 1970: 221-35
8. Schwartz JC, Lampart C, Rose C. Property and regional distribution of histidine de-carboxylase in rat brain. J Neurochem 1970; 17: 1527-34
9. Snyder SH, Taylor KM. Isotopic microassay of histamine, histidine decarboxylase and histamine methyltransferase in brain tissue. J Neurochem 1972; 19: 1343-58
10. Watanabe T, Taguchi Y, Hayashi H. Distribution of the histaminergic neuron system in the central nervous system of rats: a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker. Brain Res 1984; 295: 13-25
11. Panula P, Yang HYT, Costa E. Histamine-containing neurons in the rat hypothalamus. Proc Natl Acad Sci USA 1984; 81: 2572-6
12. Steinbusch HW, Sauren Y, Groenewegn H, et al. Histaminergic projections from the premammillary and posterior hypothalamic region to the caudate-putamen in the rat. Brain Res 1986; 363: 389-93
13. Wada H, Inagaki N, Yamatodani A. Is the histaminergic neuron system a regulatory center for whole brain activity? Trends Neurosci 1991; 14: 415-9
14. Onodera K, Yamatodani A, Watanabe T, et al. Neuropharmacology of the histaminergic neuron system in the brain and its relationship with behavioral disorders. Prog Neurobiol 1994; 42: 685-702
15. Onodera K, Watanabe T. Possible roles of brain histamine H3 receptors and the pharmacology of its ligands. Jpn J Psychopharmacol 1995; 15: 87-102
16. Schwartz JC, Arrang JM, Garbarg M, et al. Histaminergic transmission in the mammalian brain. Physiol Rev 1991; 71: 1-51
17. Przegalinsky E. Monoamines and the pathophysiology of seizure disorders. In: Frey HH, Janz D, editors. Antiepileptic drugs. Handbook of experimental pharmacology. Vol 74. Berlin: Springer, 1985: 101-30
18. Jimenez-Rivera CA, Waterhouse BD. The role of cental noradrenergic systems in seizure disorders. In: Fissher RS, Coyle JT, editors. Neurotransmitters and epilepsy: frontiers of clinical neuroscience. Vol 11. New York: Wily-Liss Inc., 1991: 109-30
19. Segal M. Serotonin and epilepsy. In: Fissher RS, Coyle JT, editors. Neurotransmitters and epilepsy: frontiers of clinical neuroscience. Vol 11. New York: Wily-Liss Inc., 1991: 103-8
20. Gerald MC, Richter NA. Studies on the effects of histaminergic agents on seizure susceptibility in mice. Psychopharmacologia 1976; 46: 277-82
21. Tuomisto L, Tacke U. Is histamine an anticonvulsive inhibitory transmitter? Neuropharmacology 1986; 25: 955-8
22. Scherkl R, Hashem A, Frey HH. Histamine in the brain - its role in regulation of seizure susceptibility. Epilepsy Res 1991; 10: 111-8
23. Yokoyama H, Onodera K, Maeyama K, et al. Histamine levels and clonic convulsions of electrically-induced seizures in mice: the effects of α-fluoromethylhistidine and metoprine. Naunyn Schmiedebergs Arch Pharmacol 1992; 346: 40-5
24. Onodera K, Tuomislo L, Tacke U, et al. Strain differences in regional brain histamine levels between genetically epilepsy prone and -resistant rat. Methods Find Exp Clin Pharmacol 1992; 14: 13-6
25. Yokoyama H, Onodera K, Iinuma K, et al. Effect of thioperamide, a histamine H3 receptor antagonist, on electrically induced convulsions in mice. Eur J Pharmacol 1993; 234: 129-33
26. Yokoyama H, Onodera K, Maeyama K, et al. Clobenpropit (VUF-9153), a new histamine H3 receptor antagonist, inhibits electrically induced convulsions in mice. Eur J Pharmacol 1994; 260: 23-8
27. Yokoyama H, Onodera K, Iinuma K, et al. 2-Thiazolylethylamine, a selective histamine H1 agonist, decreases seizure susceptibility in mice. Pharmacol Biochem Behav 1994; 47: 503-7
28. Fairbairn S, Sturman G. The influence of central histaminergic modification on the susceptibility of mice to chemically-induced seizures (abstract). Br J Pharmacol 1989; 97 Suppl.: 317
29. Yokoyama H, Onodera K, Iinuma K, et al. The proconvulsant effect of histamine H1 antagonists in developing mice. Psychopharmacology 1993; 112: 199-203
30. Yagi T, Yokoyama H, Onodera K, et al. The role of central histaminergic neuron system on electrically-induced convulsions in developing mice: effects of L-histidine and α-fluoromethylhistidine [abstract]. Jpn J Psychopharmacol 1993; 13: 384
31. Garrison JC. Hislamine, bradykinin, 5-hydroxytryptamine and their antagonists. In: Gilman AF, Rall TW, Nies AS, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 575-99
32. Nicholson AN, Pascoe PA, Turner C, et al. Sedation and histamine H1-receptor antagonism: studies in man with enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 1991; 104: 270-6
33. Goodman LS, Gilman A. Histamine and antihistaminic agents. In: Goodman LS, Gilman A. The pharmacological basis of therapeutic. 2nd ed. New York: Macmillan Company, 1960: 575-99
34. Churchill JA, Gammon OD. The effect of antihistaminic drugs on convulsive seizures. JAMA 1949; 141: 18-21
35. Wyngaarden JB, Seevers MH. The toxic effects of antihistaminic drugs. JAMA 1951; 145: 277-83
36. Schwartz JF, Patterson JH. Toxic encephalopathy related to antihistamine-barbiturate antiemetic medication. Am J Dis Child 1978; 132: 37-9
37. Mueller MS. Phenylpropanolamine, a nonprescription drug with potentially fatal side effects [letter]. N Engl J Med 1983; 308: 653
38. Bernstein E, Diskant BM. Phenylpropanolamine; a potentially hazardous drug. Ann Emerg Med 1982; 11: 311-5
39. Yasuhara K, Harada Y, Ochi F, et al. 2 cases of West syndrome and ketotifen treatment [abstract]. J Jpn Pediatr Soc 1995; 99: 112
40. Shilva MR, Antonio A. Bioassay of antihistaminic action. In: Shilva MR, editor. Handbook of experimental pharmacology XVIII/2 histamine 11 and antihistaminics. Berlin: Springer, 1978: 381-438
41. 4L Yokoyama H, Iinuma K, Yanai K, et al. Proconvulsant effect of ketotifen, a histamine H1 antagonist, confirmed by the use of d-chlorpheniramine with monitoring electroencephalography. Methods Find Exp Clin Pharmacol 1993; 15: 183-8
42. Noguchi S, Inukai T, Kuno T, et al. The suppression of olfactory bulbectomy-induced muricide by antidepressant and antihis-taminics via histamine H1 receptor blocking. Physiol Behav 1992; 51: 1223-7
43. Yokoyama H, Iinuma K, Yagi T, et al. Histaminergic neurons and epilepsies - clinical view. Methods Find Exp Clin Pharmacol 1996; 18 Suppl. A: 181-6
44. Haslam RHA. The nervous system. In: Hehrman KE, Kliegman KM, Nelson WE, et al., editors. Nelson textbook of pediatrics, 14th ed. Philadelphia: WB Saunders Company, 1992: 1473-538
45. Galland MC, Griguer Y, Morange-Sala S, et al. Convulsions fébriles: faut-il contre-indiquer certains médicaments. Therapie 1992; 47: 409-14
46. Shimoda Y, Koizumi A, Tanaka K. Electroencephalographic activation of 'diencephalic epilepsy with diphenhydramine. Yonago Acta Med 1960; 4: 99-102
47. King G, Weeks SD. Pyribenzamine activation of the electroencephalogram. Electroencephalogr Clin Neurophysiol 1965; 18: 503-7
48. Yanai K, Watanabe T, Yokoyama H, et al. Histamine H1 receptors in human brain visualized in vivo by 11C-doxepin and positron emission tomography. Neurosci Lett 1992; 137: 145-52
49. Yamatogi Y. Seizures and classification of epilepsies. In: Matsutomo R, editor. Treatment of intractable epilepsies. Tokyo: Budosha, 1991: 33
50. Ghadini H, Partington MW, Hunter A. A familial disturbance of histidine metabolism. N Engl J Med 1961; 265: 211-24
51. Imamura I, Watanabe T, Hase Y, et al. Histamine metabolism in patients with histidinemia: determination of urinary levels of histamine, N tau-methylhistamine, imidazole acetic acid, and its conjugates. J Biochem Tokyo 1984; 96: 1925-9
52. Aoki K. Revision of the nutritional management of histidinemia. Shouni-Igaku 1989; 22: 265-77
53. Nistico G, Morselli P, Lloyd KG, et al, editor. Neurotransmitters, seizures and epilepsy. III. New York: Raven Press, 1986
54. Frost JJ, Mayberg HS, Fisher RS, et al. Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann Neurol 1988; 23: 231-7
55. Savic I, Persson A, Roland P, et al. In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 1988; 11: 863-6
56. Iinuma K, Yokoyama H, Otsuki T, et al. Histamine H1 receptors in complex partial seizures [letter]. Lancet 1993, 341: 238
57. Yokoyama H, Yanai K, Iinuma K, et al. Mapping of histamine H1-receptors with complex partial seizures with PET and 11C-doxepin. In: Uemura K, editor. Quantification of brain function, tracer kinetics and image analysis in brain PET. Amsterdam: Elsevier Science Publishers, 1993: 297-301
58. Mcmillen MA, Amibs D, Siegel JH. Cimetidine and mental confusion. N Engl J Med 1978; 298: 284-5
59. Edmonds ME, Ashford RFU, Brenner MK, et al. Cimetidine: does neurotoxicity occur? Report of three cases. J R Soc Med 1979; 72: 172-5
60. Sweden BV, Kamphuisen HAC. Cimetidine neurotoxicity: EEG and behaviour aspects. Eur Neurol 1984; 23: 300-5
61. Vial T, Goubier C, Bergeret A, et al. Side effects of ranitidine. Drug Saf 1991; 6: 94-117
62. Totte J, Scharpe S, Verkerk R, et al. Neurological dysfunction associated with abnormal levels of Cimetidine metabolite [letter]. Lancet 1978; 1: 1047
63. Oishi R, Itoh M, Nishibori M, et al. Effects of the histamine H3 receptor agonist (R)-α-methylhistamine and the antagonist thioperamide on histamine metabolism in the mouse and rat brain. J Neurochem 1989; 52: 1388-94
64. Mochizuki T, Ymatodani A, Okakura K, et al. In vivo release of neuronal histamine in the hypothalamus of rats measured by microdialysis. Naunyn Schmiedebergs Arch Pharmacol 1991; 343: 190-5
65. Schlicker E, Behling A, Lummen G, et al. Histamine H3A receptor-mediated inhibition of noradrenaline release in the mouse brain cortex. Naunyn Schmiedebergs Arch Pharmacol 1992; 345: 489-93
66. Schlicker E, Betz R, Gothert M. Histamine H3 receptor mediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 1988; 337: 588-90
67. Clapham J, Kilpatrick GJ. Histamine H3 receptors modulate the release of [3H]acetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes. Br J Pharmacol 1992; 107: 919-23
68. Phillip A. Interactions with other neuron systems. In: Watanabe T, Wada H, editors. Histaminergic neurons: morphology und function, Boca Raton: CRC Press, 1991: 323-43
69. Murakami K, Yokoyama H, Onodera K, et al. AQ0145, a newly developed histamine H3-antagonist decreased seizure susceptibility of electrically-induced convulsions in mice. Methods Find Exp Clin Phamacol 1995; 17 Suppl. C: 70-3
70. Leurs R, Timmerman H. The histamine H3 receptors: a target for developing new drugs. In: Jucker E, editor. Progress in drug research. Vol. 39. Berlin: Birckhauser, 1992: 127-65